Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Exagen (XGN) Return on Equity (2019 - 2026)

Exagen filings provide 8 years of Return on Equity readings, the most recent being 0.01% for Q1 2026.

  • On a quarterly basis, Return on Equity rose 1.0% to 0.01% in Q1 2026 year-over-year; TTM through Mar 2026 was 0.01%, a 1.0% increase, with the full-year FY2025 number at 0.01%, down 1.0% from a year prior.
  • Return on Equity hit 0.01% in Q1 2026 for Exagen, down from 0.01% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.0% in Q1 2022 to a low of 0.02% in Q1 2025.
  • Median Return on Equity over the past 5 years was 0.01% (2023), compared with a mean of 0.01%.
  • Biggest five-year swings in Return on Equity: decreased -1bps in 2022 and later rose 1bps in 2026.
  • Exagen's Return on Equity stood at 0.01% in 2022, then grew by 4bps to 0.01% in 2023, then crashed by -43bps to 0.01% in 2024, then increased by 17bps to 0.01% in 2025, then decreased by -13bps to 0.01% in 2026.
  • The last three reported values for Return on Equity were 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025) per Business Quant data.